Tag: Regeneron Pharmaceuticals

November 8, 2018 Off

FDA prioritizes Dupinex for review

By Dino Mustafić

The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the @Regeneron Pharmaceuticals and Sanofi made supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis, whose disease was inadequately controlled with topical therapies or for whom topical treatment was medically inadvisable.

May 23, 2017 Off

Sanofi and Regeneron win FDA approval for its rheumatoid arthritis drug

By Dino Mustafić

The U.S. Food and Drug Administration (FDA) has approved Sanofi’s and Regeneron Pharmaceuticals’s Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).